Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Phase Ia, Safety and Immunogenicity Dose Escalation Clinical Trial to Evaluate Vaccine Against Ricin Toxin (RiVax) in Human Volunteers

Next Previous
X
Search
Trial Profile

A Pilot Phase Ia, Safety and Immunogenicity Dose Escalation Clinical Trial to Evaluate Vaccine Against Ricin Toxin (RiVax) in Human Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ricin vaccine (Primary)
  • Indications Ricin poisoning
  • Focus Adverse reactions; First in man; Pharmacodynamics

    • Most Recent Events

    • 13 Feb 2008 New trial record.
    • 14 Feb 2006 According to results published in the Proceedings of the National Academy of Sciences of the United States of America, this study was conducted under an investigational new drug application submitted to the Food and Drug Administration.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top